Month: August 2024

– Patients dosed in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne); Dosing was well tolerated in all patients with initial data expected Q4 2024 – – Solid plans to expand patient dosing with additional clinical trial sites in the U.S., Canada and Europe and plans accelerated production of multiple GMP batches of SGT-003 to support trial expansion – – Targeting the submission of 3-4 INDs by the end of 2026, strategically selecting cardiac and neuromuscular diseases with large patient populations and high unmet need – including SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT); CPVT IND submission expected in 1H 2025 – – Company ends Q2 2024 with approximately $190.3 million in cash, cash equivalents, and available-for-sale securities; Solid...

New Program Wins and Improving Gross Margins SPOKANE VALLEY, Wash., Aug. 13, 2024 (GLOBE NEWSWIRE) — Key Tronic Corporation (Nasdaq: KTCC), a provider of electronic manufacturing services (EMS), today announced its results for the quarter and fiscal year ended June 29, 2024. For the fourth quarter of fiscal year 2024, Key Tronic reported total revenue of $125.7 million, compared to $162.6 million in the same period of fiscal year 2023. For the full year of fiscal 2024, total revenue was $559.4 million, compared to $588.1 million for fiscal year 2023. As previously disclosed, a cybersecurity incident caused disruptions and limited access to portions of the Company’s business applications supporting operations and corporate functions at its Mexico and U.S. sites during the fourth quarter of fiscal 2024. During the disruption of business,...

PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab to treat metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of December 28, 2024 MIAMI, Aug. 13, 2024 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2024. Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said, “We had a very productive first half...

– Greenhouse 5 completed its first full quarter of production and sales in Q2, outperforming expectations– Record quarterly highs included consolidated revenue and gross profit, wholesale biomass revenue and gross profit, biomass production and sales and retail revenue– Second Quarter 2024 Revenue was $53.9 million, at the high end of the guidance range and up 21% year- over-year– Biomass production was more than 149,000 pounds, 20,000 pounds ahead of the mid-point of guidance and up 45% year- over-year– Quarter-end cash and restricted cash balance was $25.9 million– Q3 2024 revenue projected at a record quarterly high of $65 million to $67 million– Q3 2024 quarter-end cash and restricted cash balance projected to be $38 million to $40 million, a new high since completion of...

– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy participants – – Completed IPO and private placement raising gross proceeds of $250M – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2024, and provided a summary of recent corporate achievements and upcoming milestones. “We have made significant progress across our entire business, achieving several critical development and corporate milestones to support...

– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM for the clinical development of SENTI-202 – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the second quarter of 2024 and provided a summary of recent corporate and pipeline highlights. “We have demonstrated important progress year to date, dosing patients in our Phase 1 clinical trial of SENTI-202 in AML and continuing to execute on our development pipeline priorities,” said Timothy Lu, MD, PhD, Chief...

– Continued Momentum in Revenue Growth Leads to Highest Second Quarter Revenue Performance Since 2009 – SEATTLE, Aug. 13, 2024 (GLOBE NEWSWIRE) — Jones Soda Co. (CSE: JSDA, OTCQB: JSDA) (“Jones Soda” or the “Company”), a beverage innovation company focused on developing, marketing and distributing cutting edge consumer drink and wellness products and a leading brand in the cannabis infused beverage category space, announced its financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights vs. Year-Ago QuarterRevenue increased 49% to $7.2 million compared to $4.8 million. The second quarter of 2024 included approximately $1.2 million in revenue from the Company’s Mary Jones business compared to approximately $400,000 in the second quarter of 2023. Gross profit as a percentage of revenue...

DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the second quarter ending June 30, 2024. The Company’s revenue for three months ended June 30, 2024, was $4.7 million versus $5.5 million for three months ended June 30, 2023, a decrease of 15%. Net loss was $0.8 million, or $0.14 per share, compared to a net loss of $0.7 million, or $0.13 per share, for the three months ended June 2024 and 2023, respectively. The Company’s revenue for six months ended June 30, 2024, was $10.1 million versus $11.4 million for six months ended June 30, 2023, a decrease of 12%. Net loss was $1.5 million, or $0.26 per share, compared to a net loss of $1.1 million, or $0.19 per share, for the six months ended June 2024...

LOUISVILLE, Ky., Aug. 13, 2024 (GLOBE NEWSWIRE) — LogicMark, Inc. (Nasdaq: LGMK), a provider of personal safety, personal emergency response systems (PERS), health communications devices, and technology for the growing care and safety economy, today announced financial results for the quarter ended June 30, 2024. Summary:           Revenues were $2.3 million, up slightly compared with the prior year period. Gross margin in the second quarter of 2024 was 67%, compared with 69% for the second quarter of 2023. Overall operating expenses were $3.6 million, compared with $3.9 million for the prior year period. The cash balance on June 30, 2024 was $3.0 million. The Company’s intellectual property portfolio is expanding, with 14 patents filed since June 2021. This includes five provisional patents, three awarded patents, and the remaining...